Assembly Biosciences, Inc. (ASMB)
$
14.15
-0.05 (-0.35%)
Key metrics
Financial statements
Free cash flow per share
-7.4878
Market cap
103.6 Million
Price to sales ratio
4.5553
Debt to equity
0.1113
Current ratio
2.0486
Income quality
1.4077
Average inventory
0
ROE
-1.3177
Technology
Technology – consumer electronics
Largecap
With a market cap of 121,78 bil stock is ranked 1
Low risk
ISS score of this stock is ranked 1
Company description
Profile
Assembly Biosciences, Inc. is a clinical-stage biotechnology company focused on discovering and developing therapeutic candidates for the treatment of hepatitis B virus (HBV) infection in the United States. The company's lead product candidate, Vebicorvir, has successfully completed Phase 2 clinical trials aimed at treating patients with chronic HBV infection. Additionally, Assembly is advancing ABI-H3733, which has completed Phase 1a clinical studies, and ABI-4334, currently undergoing pre-clinical trials for HBV treatment. The financial performance of the company illustrates its potential, with an earnings per share (EPS) reported at -$6.69 indicating the company's profitability on a per-share basis. Moreover, the income before tax ratio stands at -1.40 reflecting the pre-tax margin of its operations. The company has reported depreciation and amortization expenses of $129,000.00 highlighting the wear and tear of its assets. Further, the net income ratio is -1.41 providing insight into the company’s profitability margin, while the gross profit ratio at 1.00 emphasizes the efficiency of its production and sales operations. Collaborations with BeiGene, Ltd., Arbutus Biopharma Corporation, and Antios Therapeutics, Inc. are part of its strategic efforts to evaluate a triple combination treatment for chronic HBV. Additionally, strategic license agreements with Indiana University Research and Technology Corporation and Door Pharmaceuticals, LLC reinforce the company’s innovative initiatives. Established in 2005 and formerly known as Ventrus Biosciences, Inc., Assembly Biosciences, Inc. changed its name in June 2014 and is headquartered in South San Francisco, California. Currently, the stock is affordable at $14.20 suitable for budget-conscious investors. Despite having a low average trading volume of 24,307.00 which indicates lower market activity, the company boasts a market capitalization of $108,071,333.00 classifying it as a small-cap player. Assembly Biosciences is a key player in the Biotechnology industry, contributing significantly to the overall market landscape. Furthermore, it belongs to the Healthcare sector, driving both innovation and growth within its field. The company’s efforts are crucial for the development of effective therapies for HBV, marking its importance in the biotechnology sector.
Is Assembly Biosciences, Inc. (ASMB) a good investment?
Investing in Assembly Biosciences, Inc. (ASMB) depends on multiple factors, including revenue growth, profit margins, debt-to-equity ratio, earnings per share, and return on equity. Analysts have rated it as C-, with a Bullish outlook. Always conduct your own research before investing.
What is Assembly Biosciences, Inc. (ASMB)'s stock forecast?
Analysts predict Assembly Biosciences, Inc. stock to fluctuate between $7.75 (low) and $19.93 (high) in the next 365 days, reflecting market expectations and potential volatility.
What is Assembly Biosciences, Inc.'s market capitalization?
As of 2025-05-30, Assembly Biosciences, Inc.'s market cap is $108,071,333, based on 7,637,550 outstanding shares.
How does Assembly Biosciences, Inc. compare to competitors like Eli Lilly & Co.?
Compared to Eli Lilly & Co., Assembly Biosciences, Inc. has a Lower Market-Cap, indicating a difference in performance.
How can I buy Assembly Biosciences, Inc. (ASMB) stock?
To buy Assembly Biosciences, Inc. (ASMB) stock: Open a brokerage account (e.g., Robinhood, TD Ameritrade, E-Trade). Search for ASMB. Place an order (Market, Limit, etc.).
What is the best time to invest in Assembly Biosciences, Inc.?
The best time to invest depends on market trends and technical indicators, which show a Bullish trend based on economic conditions and company performance.
Has Assembly Biosciences, Inc. stock ever split?
Assembly Biosciences, Inc.'s last stock split was 1:12 on 2024-02-12.
How did Assembly Biosciences, Inc. perform in the last earnings report?
Revenue: $28,520,000 | EPS: -$6.69 | Growth: -50%.
Where can I find Assembly Biosciences, Inc.'s investor relations reports?
Visit https://www.assemblybio.com/investor-relations for detailed financial reports.
Where can I find historical stock prices for Assembly Biosciences, Inc.?
You can explore historical data from here
What is the all-time high and low for Assembly Biosciences, Inc. stock?
All-time high: $84.24 (2021-02-10) | All-time low: $7.69 (2023-11-22).
What are the key trends affecting Assembly Biosciences, Inc. stock?
Key trends include market demand, economic conditions, interest rates, and industry competition, which influence the stock's performance.
News
globenewswire.com
4 days ago
SOUTH SAN FRANCISCO, Calif., May 27, 2025 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a biotechnology company developing innovative therapeutics targeting serious viral diseases, today announced that Jason Okazaki, chief executive officer and president, and Anuj Gaggar, MD, PhD, chief medical officer, will present in a fireside chat during the Jefferies 2025 Global Healthcare Conference at 8:45 a.m. Eastern Time on June 4, 2025. A live webcast will be available on the Events and Presentations section of Assembly Bio's website and a replay will be accessible following the event. To register for the live webcast and replay, please visit: https://investor.assemblybio.com/events-presentations.
zacks.com
23 days ago
Assembly Biosciences (ASMB) came out with a quarterly loss of $1.17 per share versus the Zacks Consensus Estimate of a loss of $2.01. This compares to loss of $1.66 per share a year ago.
globenewswire.com
23 days ago
– Ongoing clinical studies for four candidates on track with data expected in 2025, including interim Phase 1b data for long-acting helicase-primase inhibitors ABI-5366 and ABI-1179 anticipated in fall 2025 –
globenewswire.com
25 days ago
– Late-breaker poster highlights preclinical profile of ABI-6250, currently in Phase 1a with data anticipated in Q3 2025 – – Second poster describes in vitro studies of effects on viral infection markers by ABI-4334, currently in Phase 1b with data anticipated in the first half of 2025 – SOUTH SAN FRANCISCO, Calif., May 07, 2025 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a biotechnology company developing innovative therapeutics targeting serious viral diseases, today announced new preclinical and in vitro data for two therapeutic candidates featured in poster presentations, including one late-breaker, at the European Association for the Study of the Liver (EASL) Congress, taking place May 7-10, 2025, in Amsterdam, the Netherlands.
zacks.com
a month ago
Assembly Biosciences (ASMB) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
globenewswire.com
2 months ago
– Clinical and preclinical data supporting dosing profile and tolerability for ABI-5366, a novel long-acting helicase-primase inhibitor candidate, featured in two poster presentations –
zacks.com
2 months ago
The heavy selling pressure might have exhausted for Assembly Biosciences (ASMB) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
zacks.com
2 months ago
Assembly Biosciences (ASMB) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
globenewswire.com
2 months ago
– Four development candidates in clinical studies with data anticipated this year, continuing rapid progress of antiviral pipeline –
globenewswire.com
3 months ago
– Phase 1a study will evaluate single and multiple ascending doses of ABI-6250 in healthy participants with data expected in Q3 2025 – – Biomarker of ABI-6250 target engagement, serum bile acids, will be assessed in addition to safety and pharmacokinetic measures – SOUTH SAN FRANCISCO, Calif., Feb. 26, 2025 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a biotechnology company developing innovative therapeutics targeting serious viral diseases, today announced that the first participant has been dosed in the Phase 1a trial of ABI-6250, the company's orally bioavailable, small molecule hepatitis delta virus (HDV) entry inhibitor candidate.
See all news
